Top Pharmaceutical Companies in Boston, MA (117)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Profitability: Margins and earnings are expanding, with Q1 FY2026 adjusted EBITDA up, gross margin at 30.1%, and positive net income. FY2025 also delivered record free cash flow alongside margin expansion.
Customer Loyalty & Retention: Autoship represents a large, recurring base at 84.4% of Q1 FY2026 net sales, growing at a double‑digit pace. Rising net sales per active customer and cross‑category engagement point to stickier spend and retention.
Diversified Revenue Streams: Pet health services are scaling through SmartPak and the Modern Animal acquisition, complementing core e‑commerce with clinics and pharmacy. The Modern Animal deal is expected to add over $125M in annualized run‑rate revenue and expand clinics from 18 to 47, with additional openings planned in FY2026.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Formation Bio closed a $372M Series D on June 26, 2024 led by a16z with significant participation from Sanofi, bringing total funding to over $600M and at a material step-up in valuation. The capital is directed toward expanding its drug pipeline and AI platform.
Strategic Partnerships: A first‑in‑class AI collaboration with Sanofi and OpenAI (announced May 2024) has already produced Muse, an AI tool for patient recruitment. Additional partnering activity includes Sanofi’s 2025 deal for gusacitinib via a Formation subsidiary, signaling expanding commercial and technology ties.
Product Line Growth: Multiple in‑licensing moves in 2025–2026 (e.g., a CNS‑penetrant TYK2 inhibitor, a miR‑124 activator, and an anti‑CD226 program) broaden the portfolio. The first participant was dosed in a Phase 1 trial (BLKR201) on June 9, 2026, marking concrete clinical progression.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.
Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.
Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused...
Vertex Pharmaceuticals's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company materials depict Vertex as a leader with near‑dominance in cystic fibrosis and first‑mover approvals in CRISPR‑based gene editing. This is supported by broad real‑world CF impact and landmark authorizations for Casgevy.
Strong Revenue Growth: Reported year‑over‑year revenue growth in 2025 and raised guidance for 2026 indicate ongoing momentum. Quarterly performance aligned with or exceeded guidance during the year, underscoring execution against growth plans.
Diversified Revenue Streams: Early contributions in 2025 from Alyftrek, Journavx, and Casgevy, with management signaling higher non‑CF revenues in 2026, show a broadening base beyond CF. Guidance highlighting non‑CF contribution points to increasing mix diversification over the near term.
At Via Separations, we take a materials approach to the world's wasted energy. We are optimistic about scientific progress, passionate about global impact, and creative in everything we do. We are not afraid of hard problems, and we encourage each other to live at the intersections of disciplines, act on great ideas, and design everything. Via eliminates energy use in...
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in. We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and...
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. We are powered...
Novo Nordisk's Top Stability & Growth Strengths
Strong Market Position & Advantage: Novo Nordisk is characterized as a global leader in GLP‑1–based diabetes and obesity care, anchored by clinically differentiated products like Wegovy and a broad GLP‑1 portfolio. While shares fluctuate by geography, disclosures and independent analyses continue to frame the company as a category leader.
Innovation-Driven Growth: Cardiovascular outcomes data supporting Wegovy’s label expansion and the first approved oral GLP‑1 for chronic weight management, together with late‑stage assets (e.g., amycretin/zenagamtide, CagriSema), strengthen adoption arguments and extend the franchise.
Market Expansion: U.S. launch momentum for the Wegovy pill, EU approval, and planned international rollouts in 2026 are broadening access and the addressable market. Significant capacity additions, including acquired fill‑finish sites and new investments, are intended to support higher volumes across regions.
Brand Protection ,Tracking & Engagement | Smart & Connected Packaging for Pharmaceutical | FMCG | Agro | and many more industry applications. Ennoventure Inc. was started in 2018 as an innovative venture with the aims of developing digital solutions , using advanced technologies like AI, Block chain and embedded solutions. Company has its headquarters in Massachusetts, USA and R&D center in...
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and change how brain disorders are thought about and treated. Our mission is to pioneer solutions with the potential to deliver life-changing...
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and...
Multiply Labs develops advanced robotic systems that manufacture individualized drugs at scale. Our products are enabled by the combination of pharmaceutical science with robotics technology. Multiply Labs has built and operates a unique robotic pharmaceutical manufacturing facility in San Francisco.
ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and liquid tumors, as well as several of the...
The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited. The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase...
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to...
Callen-Lorde is the global leader in LGBTQ+ healthcare. Since the days of Stonewall, we have been transforming lives in LGBTQ+ communities through excellent comprehensive care, provided free of judgment and regardless of ability to pay. In addition, we are continuously pioneering research, advocacy and education to drive positive change around the world, because we believe healthcare is a human right.
ArisGlobal is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® boosts efficiency, ensures...
.png)
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The...
Prudentia’s AI-powered technology accelerates investment in breakthrough therapies that change the world.
BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several...
